Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Bixlenvo is a brand-new, once-daily single-tablet regimen (STR) combining bictegravir (75 mg) and lenacapavir (50 mg). Developed by Gilead Sciences, it earned U.S. FDA approval on August 27, 2026, making it the first daily pill engineered specifically to replace complex, multi-tablet therapies for virologically suppressed adults living with HIV.
Bixlenvo is a brand-new, once-daily single-tablet regimen (STR) combining bictegravir (75 mg) and lenacapavir (50 mg). Developed by Gilead Sciences, it earned U.S. FDA approval on August 27, 2026, making it the first daily pill engineered specifically to replace complex, multi-tablet therapies for virologically suppressed adults living with HIV.